EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers

Rameesha Rauf iD, Salwa Asif iD, Abdallah AlSaafeen iD, Kaviprada Geathaa Dhantapaani iD, Maryam Muhammad Nadeem iD, Zohra Kamran Rao iD, Aliya Shaju Shahul Hameed iD, Karthik Chintharala iD, Muhammad Faheem Anwar iD, Asad Ali Ahmed Cheema iD

Brain and Behavior · 2025

DOI: 10.1002/brb3.70984 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain and Behavior, 2025. Verfasst von Rameesha Rauf und 9 weiteren Autor:innen. Beteiligte Einrichtung: Tbilisi State Medical University, Tbilisi, Georgia. Hauptthemen laut MEDLINE: Narcolepsy, Orexins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Narcolepsy Type 1 (NT1) is a chronic neurological disorder characterized by excessive daytime sleepiness (EDS), cataplexy, and REM intrusions, caused by a deficiency of orexin (hypocretin), a hypothalamic neuropeptide essential for arousal, REM sleep regulation, metabolism, and emotional stability. This review synthesizes and critically analyzes the pathophysiological, clinical, and therapeutic dimensions of orexin deficiency in narcolepsy, with particular emphasis on recent advances from 2023 to 2025.

Methods

This narrative analytical review analyzed 50 peer‐reviewed publications covering the neurobiology of the orexin system, diagnostic evolution of NT1, comparative symptomatology of central hypersomnia disorders, and recent therapeutic innovations. Out of which 16 studies were selected based on relevance, recency, and translational impact.

Results

Recent research confirms that over 90% of NT1 patients exhibit cerebrospinal fluid (CSF) orexin‐A levels below 110 pg/mL and carry the HLA‐DQB1*06:02 allele, indicating a strong genetic and immunological association. Postmortem analyses have revealed a loss of up to 95% of orexin‐producing neurons in the lateral hypothalamus. In a 2024 multicenter trial, danavorexton (a selective orexin receptor‐2 [OX2R] agonist) was associated with a mean improvement of 11.1 points on the Maintenance of Wakefulness Test, outperforming modafinil and suggesting the feasibility of receptor‐level restoration. In addition, intermediate orexin levels (110–200 pg/mL) have been documented in a subset of patients with narcolepsy Type 2 (NT2) and idiopathic hypersomnia (IH), challenging the binary diagnostic threshold and prompting reevaluation of orexin's diagnostic role. Orexin dysfunction has also been correlated with high psychiatric comorbidity rates, including major depressive disorder in 40% and anxiety disorders in nearly 30% of NT1 patients. These manifestations reflect orexin's broader role in regulating REM sleep, metabolic processes, and autonomic stability.

Conclusion

Orexin deficiency remains the central mechanism underlying NT1, with far‐reaching implications in psychiatric and neurodegenerative disease. While emerging orexin‐targeted therapies offer promising disease‐modifying potential, critical challenges persist in standardizing biomarkers, resolving NT2 classification ambiguities, and ensuring global access to therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NarcolepsyOrexinsHumansPhenotypeAnimalsHypothalamusOrexin Receptors

Stichwörter der Autor:innen

autoimmune neurodegenerationhypocretinnarcolepsy Type 1orexin deficiencysleep–wake regulationtherapeutic targets

Substanzen

OrexinsOrexin Receptors

Autor:innen und Institutionen

  • Tbilisi State Medical University, Tbilisi, Georgia.
  • EUMD, General Medicine, Tbilisi State Medical University, Tbilisi, Georgia.
  • Nantong Medical University, Nantong City, China.
  • Tbilisi State University, Tbilisi, Georgia.
  • East European University, Tbilisi, Georgia.
  • NRI Academy of Medical Sciences, Guntur, India.

ORCID-Profile: Rameesha Rauf, Salwa Asif, Abdallah AlSaafeen, Kaviprada Geathaa Dhantapaani, Maryam Muhammad Nadeem, Zohra Kamran Rao, Aliya Shaju Shahul Hameed, Karthik Chintharala, Muhammad Faheem Anwar, Asad Ali Ahmed Cheema

Zitieren

APA

Rauf, R., Asif, S., AlSaafeen, A., Dhantapaani, K. G., Nadeem, M. M., Rao, Z. K., Hameed, A. S. S., Chintharala, K., Anwar, M. F., & Cheema, A. A. A. (2025). Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers. Brain and Behavior. https://doi.org/10.1002/brb3.70984

Vancouver

Rauf R, Asif S, AlSaafeen A, Dhantapaani KG, Nadeem MM, Rao ZK, et al. Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers. Brain and Behavior. 2025. doi:10.1002/brb3.70984

BibTeX
@article{Rauf2025,
  author = {Rauf, Rameesha and Asif, Salwa and AlSaafeen, Abdallah and Dhantapaani, Kaviprada Geathaa and Nadeem, Maryam Muhammad and Rao, Zohra Kamran and Hameed, Aliya Shaju Shahul and Chintharala, Karthik and Anwar, Muhammad Faheem and Cheema, Asad Ali Ahmed},
  title = {Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers},
  journal = {Brain and Behavior},
  year = {2025},
  doi = {10.1002/brb3.70984}
}
Kostenlos starten →